5 结果
The present invention relates to Tumor Necrosis Factor Muteins.
BACKGROUND OF THE INVENTION
Tumor Necrosis Factor, or more specifically Tumor Necrosis Factor-.alpha. (for ease of reference, unless otherwise indicated, "Tumor Necrosis Factor" or "TNF" when used herein refers to TNF-.alpha.), is a
CROSS-REFERENCE TO RELATED APPLICATIONS
This is the U.S. national phase of International Application No. PCT/CN2009/000037, filed Jan. 12, 2009, which claims the benefit of Chinese Patent Application No. 200810038410.X, filed May 30, 2008.
TECHNICAL FIELD
The present invention is in the field of
The present invention is directed to non-pathogenic, oncolytic, recombinant polioviruses for the treatment of various forms of malignant tumors. More particularly, the present invention is directed to the administration of the non-pathogenic, oncolytic, recombinant poliovirus to the tumor directly,
The present invention is directed to non-pathogenic, oncolytic, recombinant polioviruses for the treatment of various forms of malignant tumors. More particularly, the present invention is directed to the administration of the non-pathogenic, oncolytic, recombinant poliovirus to the tumor directly,
The present invention is directed to non-pathogenic, oncolytic, recombinant polioviruses for the treatment of various forms of malignant tumors. More particularly, the present invention is directed to the administration of the non-pathogenic, oncolytic, recombinant poliovirus to the tumor directly,